Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide for hospitalized congestive heart failure
NL-OMON45920Phase 2Active, not recruiting
- Sponsor
- Stealth BioTherapeutics
- Start
- Jan 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing Elamipretide with Placebo (2 arms). Primary endpoint: Change in NT-proBNP between baseline and Day 8 or early discharge. Started Jan 2017; status: active, not recruiting.
02
Drugs
elamipretide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON45920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45920.